High mobility group box-1 and its clinical value in breast cancer

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 413-419

  Sun, Shanping ^a,b   Zhang, Wei ^b   Cui, Zhaoqing ^b   Chen, Qi ^b   Xie, Panpan ^b   Zhou, Changxin ^b   Liu, Baoguo ^b   Peng, Xiangeng ^b   Zhang, Yang ^b  

^a SHANDONG UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

Breast cancer; High mobility group box 1; Serum biomarker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 84923063702     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S73366     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Fang Q, Qiong W, Zhang L, et al. Analysis of breast cancer epidemic. Chin J Soc Med. 2012;29:333–335.
3. Mantovani A. Cancer: Inflaming metastasis. Nature. 2009;457(7225):36–37.
4. Salto-Tellez M, James JA, Hamilton PW. Molecular pathology – the value of an integrative approach. Mol Oncol. 2014;8(7):1163–1168.
5. Zhang Y, Jiao J, Yang P, Lu H. Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery. Clin Proteomics. 2014;11(1):18.
6. Dos Anjos Pultz B, da Luz FA, de Faria PR, Oliveira AP, de Araujo RA, Silva MJ. Far beyond the usual biomarkers in breast cancer: a review. J Cancer. 2014;5(7):559–571.
7. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju091.
8. Gion M, Mione R, Leon AE, et al. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem. 1999;45(5):630–637.
9. Hou MF, Chen YL, Tseng TF, et al. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci. 1999;15(9):520–528.
10. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002;48(8):1296–1304.
11. Tang D, Kang R, Zeh HJ 3rd, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799(1–2):131–140.
12. Zhang J, Zhu JS, Zhou Z, et al. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo. Oncol Rep. 2012;27(5):1511–1519.
13. Völp K, Brezniceanu ML, Bösser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006;55(2):234–242.
14. Pardo M, García A, Thomas B, et al. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer. 2006;119(5):1014–1022.
15. Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are over expressed and associated with prostate cancer development. Prostate. 2005;64(1):92–100.
16. Choi YR, Kim H, Kang HJ, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res. 2003;63(9):2188–2193.
17. Hirata K, Takada M, Suzuki Y, et al. Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells. Hepatogastroenterology. 2003;50(53):1205–1207.
18. Evans A, Lennard TW, Davies BR. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol. 2004;88(2):86–99.
19. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17.
20. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 2010;337(1–2):251–258.
21. Yang GL, Zhang LH, Bo JJ, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106(1):57–61.
22. Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Aspects Med. 2014;40C:1–116.
23. Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res. 2013;19(15):4046–4057.
24. Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin. 2007;28(12):1957–1967.
25. Chalmers SA, Eidelman AS, Ewer JC, et al. A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. Cell Immunol. 2013;282(2):136–145.
26. Flohr AM, Rogalla P, Meiboom M, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res. 2001;21(6A):3881–3885.
27. Stoetzer OJ, Fersching DM, Salat C, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 2013;34(1):81–90.
28. Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68(11):4026–4030.
29. Brezniceanu ML, Völp K, Bosse S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003;17(8):1295–1297.
30. Müller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004;255(3):332–343.
31. Dolde CE, Mukherjee M, Cho C, et al. HMG-1/Y in human breast cancer cell lines. Breast Cancer Res Treat. 2002;71(3):181–191.
32. Ghavami S, Rashedi I, Dattilo BM, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008;83(6):1484–1492.
33. Palumbo R, Galvez BG, Pusterla T, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol. 2007;179(1):33–40.
34. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2004;279(7):5059–5065.
35. Ohmori H, Luo Y, Kuniyasu H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets. 2011;15(2):183–193.
36. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405(6784):354–360.
37. Schlueter C, Weber H, Meyer B, et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 2005;166(4):1259–1263.
38. Sparatore B, Patrone M, Passalacqua M, et al. Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J. 2005;389 Pt 1:215–221.
39. Chung HW, Lee SG, Kim H, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009;7:38.
40. Cheng BQ, Jia CQ, Liu CT, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008;40(6):446–452.
41. Shang GH, Jia CQ, Tian H, et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103(12):1949–1953.
42. Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J. 2009;50(5):455–464.